An update on treatment strategies for common variable immunodeficiency

Area of Science:

• Immunology
• Primary Immunodeficiency

Background:

• Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency characterized by hypogammaglobulinemia and impaired B-cell differentiation.
• The underlying molecular defects in immune regulation remain largely unknown, contributing to variable clinical severity.
• Recurrent infections are the hallmark, potentially leading to chronic organ damage and reduced quality of life.

Purpose of the Study:

• To review the clinical manifestations, diagnostic challenges, and management strategies for Common Variable Immunodeficiency.
• To highlight the impact of immunoglobulin replacement therapy on patient outcomes.
• To emphasize the importance of a multidisciplinary approach in managing CVID-related complications.

Main Methods:

• Literature review of primary immunodeficiency, focusing on Common Variable Immunodeficiency.
• Analysis of clinical data regarding infection patterns, autoimmune phenomena, and malignancies in CVID patients.
• Evaluation of the efficacy of intravenous and subcutaneous immunoglobulin therapies.

Main Results:

• Intravenous immunoglobulin (Ig) therapy has significantly improved prognosis and reduced infection rates.
• Subcutaneous Ig therapy offers improved convenience and quality of life for patients.
• Aberrant T-cell function contributes to autoimmune, inflammatory, lymphoproliferative disorders, and malignancies in a subset of patients.

Conclusions:

• Effective management of Common Variable Immunodeficiency relies on timely diagnosis and consistent immunoglobulin replacement therapy.
• Adjunct therapies, including antimicrobials and immunosuppressants, are crucial for managing specific complications.
• A comprehensive, multidisciplinary approach is essential for addressing the diverse clinical spectrum of CVID and optimizing patient care.